Which lymphomas can involve the nasopharynx?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Extranodal natural killer (NK)/T-cell lymphoma, nasal type, is the primary lymphoma that can involve the nasopharynx, as it is more common in Asia and Central and South America, and is nearly always Epstein-Barr virus-positive 1. This lymphoma type is characterized by its aggressive clinical behavior, with a median survival of 27 months for patients presenting with only skin lesions, compared with 5 months for patients presenting with cutaneous and extracutaneous diseases 1.

Key Characteristics of Extranodal NK/T-cell Lymphoma

  • More common in Asia and Central and South America
  • Nearly always Epstein-Barr virus-positive
  • Aggressive clinical behavior
  • Median survival of 27 months for patients with only skin lesions, compared with 5 months for patients with cutaneous and extracutaneous diseases

Treatment Approach

Treatment for extranodal NK/T-cell lymphoma, nasal type, typically involves radiotherapy, with recommended radiation doses of 50 Gy to the initial lesion and a boost of 5–10 Gy to residual disease 1.

Importance of Early Diagnosis

Early diagnosis is crucial, as nasopharyngeal involvement can lead to local destruction and extension to adjacent structures, highlighting the need for prompt treatment and management.

Clinical Presentation

Patients with extranodal NK/T-cell lymphoma, nasal type, may present with symptoms such as nasal obstruction, epistaxis, hearing loss, or cranial nerve palsies, emphasizing the importance of a thorough diagnostic workup, including tissue biopsy with immunohistochemistry and molecular studies.

From the FDA Drug Label

Adult patients with Non-Hodgkin's Lymphoma (NHL) Previously untreated follicular, CD20-positive, B-cell NHL Previously untreated diffuse large B-cell, CD20-positive NHL Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL)

The FDA drug label does not answer the question of which lymphomas can involve the nasopharynx.

From the Research

Lymphomas Involving the Nasopharynx

The nasopharynx can be involved by various types of lymphomas, including:

  • Diffuse large B cell lymphoma (DLBCL) 2, 3
  • NK/T cell lymphoma (NKTCL) 2, 3, 4, 5, 6
  • Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALToma) 2
  • Small lymphocytic lymphoma 2
  • Mantle cell lymphoma 2
  • Post-transplant lymphoproliferative disorder (PTLD) 2

Characteristics of Lymphomas Involving the Nasopharynx

  • Nasopharyngeal lymphoma is a rare primary malignancy of the head and neck 2
  • The most common pathological diagnosis of nasopharyngeal lymphoma is DLBCL, followed by NKTCL 2
  • EBV positivity is found in both NKTCL and DLBCL 2, 3
  • NKTCL is often associated with a worse prognosis compared to other types of lymphomas 5, 6
  • Radiotherapy and chemotherapy are common treatment modalities for lymphomas involving the nasopharynx 2, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Nasopharyngeal Lymphoma: A 22-Year Review of 35 Cases.

Journal of clinical medicine, 2019

Research

Comparison of Primary B/NKT Non-Hodgkin Lymphomas in Nasopharynx, Nasal Cavity, and Paranasal Sinuses.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2023

Research

Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998

Research

NK/T-cell lymphomas.

Best practice & research. Clinical haematology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.